↓ Skip to main content

Oncotarget

Article Metrics

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Overview of attention for article published in Oncotarget, February 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

policy
1 policy source
twitter
1 tweeter

Citations

dimensions_citation
177 Dimensions

Readers on

mendeley
117 Mendeley
Title
Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
Published in
Oncotarget, February 2016
DOI 10.18632/oncotarget.7245
Pubmed ID
Authors

Hojjat Ahmadzadehfar, Elisabeth Eppard, Stefan Kürpig, Rolf Fimmers, Anna Yordanova, Carl Diedrich Schlenkhoff, Florian Gärtner, Sebastian Rogenhofer, Markus Essler

Abstract

Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer (PC), making it an optimal target for the treatment of metastasized PC. Radioligand therapy (RLT) with 177Lu-PSMA-DKFZ-617 (Lu-PSMA) is a targeted therapy for metastatic PC. In this study, we retrospectively analyzed the side effects and the response rate of 24 hormone and/or chemorefractory PC patients with a mean age of 75.2 years (range: 64-82) with distant metastases and progressive disease according to the PSA level, who were treated with Lu-PSMA. Median PSA was 522 ng/ml (range: 17-2360). Forty-six cycles of Lu-PSMA were performed. Of the 24 patients, 22 received two cycles. Eight weeks after the first cycle of Lu-PSMA therapy 79.1% experienced a decline in PSA level. Eight weeks after the second cycle of Lu-PSMA therapy 68.2% experienced a decline in PSA relative to the baseline value. Apart from two cases of grade 3 anemia, there was no relevant hemato- or nephrotoxicity (grade 3 or 4). These results confirmed that Lu-PSMA is a safe treatment option for metastatic PC patients and has a low toxicity profile. A positive response to therapy in terms of decline in PSA occurs in about 70% of patients.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 <1%
Canada 1 <1%
Unknown 115 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 17 15%
Student > Ph. D. Student 17 15%
Student > Master 16 14%
Student > Doctoral Student 13 11%
Other 11 9%
Other 23 20%
Unknown 20 17%
Readers by discipline Count As %
Medicine and Dentistry 48 41%
Chemistry 10 9%
Pharmacology, Toxicology and Pharmaceutical Science 9 8%
Agricultural and Biological Sciences 5 4%
Biochemistry, Genetics and Molecular Biology 4 3%
Other 15 13%
Unknown 26 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 March 2021.
All research outputs
#5,288,398
of 18,846,561 outputs
Outputs from Oncotarget
#2,091
of 13,699 outputs
Outputs of similar age
#97,000
of 359,660 outputs
Outputs of similar age from Oncotarget
#95
of 817 outputs
Altmetric has tracked 18,846,561 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 13,699 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,660 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 817 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.